Semaglutide combined with automated insulin delivery enhances glucose control in type 1 diabetes, lowering insulin ...

As previously reported, Craig-Hallum initiated coverage of LifeVantage (LFVN) with a Buy rating and $35 price target Interest in weight loss ...

LifeVantage (LFVN) announced the results of a third-party cell study on the synergistic impact of Protandim Nrf2 Synergizer ...

LifeVantage Corporation (Nasdaq: LFVN), a leader in cellular activation of optimal health processes, today announced the results of a groundbreaking third-party cell study on the synergistic impact of ...

LifeVantage's new MindBody GLP-1 System is riding the coattails of GLP-1 weight loss drugs. See why I rate LFVN stock as a ...